Income StatementBalance SheetCash FlowSegments
Bristol-Myers Squibb logo

Bristol-Myers Squibb Business Segments

Business, geographic, and product segment breakdowns

Bristol-Myers Squibb generates $48.5B in annual revenue across 1 key segments: Amylin, Onglyza, and Farxiga ($88.0M). Based on the Q1 2026 filing.

Amylin, Onglyza, and Farxiga (TTM)$88.0M
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$121.42B
P/E Ratio16.69
ROE38.84%

Products & Services

Total Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Eliquis$3.2B$3.6B$3.7B$3.7B$3.5B$4.1B
Opdivo$2.5B$2.3B$2.6B$2.5B$2.7B$2.1B
Orencia$1.0B$770.0M$963.0M$964.0M$1.0B$818.0M
Yervoy$675.0M$624.0M$728.0M$739.0M$810.0M$651.0M
Other Growth products$527.0M$507.0M$470.0M$514.0M$536.0M$581.0M
Reblozyl$547.0M$478.0M$568.0M$615.0M$666.0M$555.0M
Pomalyst/Imnovid$823.0M$658.0M$708.0M$675.0M$692.0M$513.0M
Breyanzi$263.0M$263.0M$344.0M$359.0M$392.0M$411.0M
Revlimid$1.3B$936.0M$838.0M$575.0M$602.0M$349.0M
Camzyos$223.0M$159.0M$260.0M$296.0M$354.0M$314.0M
Opdualag$254.0M$252.0M$284.0M$299.0M$350.0M$295.0M
Opdivo Qvantig$0.0$9.0M$30.0M$67.0M$133.0M$163.0M
Other Legacy products$250.0M$199.0M$223.0M$177.0M$199.0M$156.0M
Zeposia$158.0M$107.0M$150.0M$161.0M$159.0M$118.0M
Sprycel$198.0M$175.0M$120.0M$119.0M$80.0M$73.0M
Sotyktu$83.0M$55.0M$70.0M$80.0M$85.0M$69.0M
Cobenfy$10.0M$27.0M$35.0M$43.0M$50.0M$56.0M
Abraxane$174.0M$105.0M$105.0M$74.0M$84.0M$50.0M
Krazati$39.0M$48.0M$48.0M$53.0M$56.0M$50.0M
Other revenue—$0.0———-$15.0M

Business sale royalty expense

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Amylin, Onglyza, and Farxiga$24.0M$22.0M$22.0M$22.0M$22.0M—

Percentage of reimbursement for development costs from alliance partner

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Eliquis60.0%———60.0%—

Concentration risk, percentage

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net product sales23.8%23.8%23.8%23.8%23.8%—

Royalty Income

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Supply Agreements$300.0M$300.0M$300.0M$300.0M$300.0M—

Geographic

Property, plant and equipment

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
International$2.3B———$2.6B—
United States$4.8B———$4.9B—

Total Revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
United States$8.6B$7.9B$8.5B$8.3B$8.6B$7.8B
International$3.4B$3.1B$3.5B$3.6B$3.6B$3.4B
Other$350.0M$218.0M$270.0M$290.0M$309.0M$257.0M

Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Ireland—-$0.0-$0.0-$0.0-$0.0—
Switzerland—-$0.0-$0.0-$0.0-$0.0—

Other

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Ireland—$0.0$0.0$0.0$0.0—
Switzerland—-$0.0-$0.0-$0.0-$0.0—

Pillar Two

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Ireland—0.1%0.1%0.1%0.1%—
Switzerland—0.1%0.1%0.1%0.1%—

Royalty rate due to regulatory approvals

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
North America1.0%1.0%1.0%1.0%1.0%—
Rest of World Except Japan, South Korea and Taiwan3.8%3.8%3.8%3.8%3.8%—

Canton

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Switzerland—0.8%0.8%0.8%0.8%—

Withholding Tax

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Switzerland—$0.0$0.0$0.0$0.0—

Gross to Net Adjustments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
United States$9.7B$8.2B$9.5B$9.8B$10.5B$4.8B